Key to our innovative approach is our focus on the target ICAM-1 (Intercellular Adhesion Molecule 1) and LFA-1 (Lymphocyte Function-Associated Antigen 1). ICAM-1, found on the surface of cancer cells, acts as a binding site for LFA-1 on T cells, facilitating their recognition and destruction of malignant cells.
By affinity tuning, AffyImmune’s CAR T cells are optimized to kill cancerous cells while avoiding damage to normal cells and tissues.
In vivo tracking of CAR T cells reduces patient burden and improves the standard of care for cancer patients. AffyImmune’s proprietary technology addresses critical challenges such as toxicity, antigen loss, T cell trafficking, and exhaustion.
ICAM-1, found on the surface of cancer cells, acts as a binding site for LFA-1 on AIC100 CAR T cells, facilitating their recognition and destruction of malignant cells.
AffyImmune has chosen ARTC as the initial indication for AIC100 and has received both Orphan Drug and Fast Track Designation from FDA; non-small cell lung cancer has been selected as the second indication.
AffyImmune Therapeutics Inc.
22 Strathmore Road,
Natick, MA, 01760
ph: (508) 654-3600
©2024 AffyImmune